Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

被引：3
|
作者：
Elshaer, Amani [1 ]
Chascsa, David M. H. [2 ,3 ]
Lizaola-Mayo, Blanca C. [2 ,3 ]
机构：
[1] Mayo Clin, Dept Internal Med, Scottsdale, AZ 85054 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Scottsdale, AZ 85054 USA
[3] Mayo Clin, Transplant Ctr, Dept Med, Scottsdale, AZ 85054 USA
来源：
LIFE-BASEL | 2024年 / 14卷 / 07期
关键词：
metabolic-associated steatotic liver disease; fibrosis; cirrhosis; obesity; weight loss; lifestyle modification; pharmacotherapy; bariatric surgery; LIFE-STYLE MODIFICATION; CLINICAL-PRACTICE UPDATE; GLUCAGON-LIKE PEPTIDE-1; CORONARY-HEART-DISEASE; FATTY LIVER; BARIATRIC SURGERY; INSULIN-RESISTANCE; WEIGHT-LOSS; NONALCOHOLIC STEATOHEPATITIS; AMERICAN ASSOCIATION;
D O I：
10.3390/life14070844
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.
引用
收藏
页数：21
相关论文
共 50 条
  • [21] The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies
    Wang, Li Jun
    Sun, Jian Guang
    Chen, Shu Cheng
    Sun, Yu Li
    Zheng, Yang
    Feng, Jian Chao
    FRONTIERS IN MEDICINE, 2025, 11
  • [22] Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)
    Canivet, C. M.
    Faure, S.
    REVUE DE MEDECINE INTERNE, 2024, 45 (01): : 41 - 47
  • [23] Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Malik, Adnan
    Javaid, Sadia
    Malik, Muhammad Imran
    Qureshi, Shahbaz
    ANNALS OF HEPATOLOGY, 2024, 29 (06)
  • [24] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [25] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [26] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [27] Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Hamamah, Sevag
    Iatcu, Oana C.
    Covasa, Mihai
    NUTRIENTS, 2025, 17 (01)
  • [28] Advances in research on metabolic dysfunction-associated steatotic liver disease
    Wang, Jiawang
    Wang, Zhongyu
    Yu, Yao
    Cheng, Si
    Wu, Jianping
    LIFE SCIENCES, 2025, 362
  • [29] Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices
    Barbhuiya, Pervej Alom
    Ahmed, Ameena
    Dutta, Partha Pratim
    Sen, Saikat
    Pathak, Manash Pratim
    CURRENT NUTRITION REPORTS, 2025, 14 (01)
  • [30] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
12345